Introduction
The BCL2 family contains a growing number of gene products that play a role in the control of cell viability. MCL1 is a member of this family that was discovered based on increased expression in ML-1 human myeloblastic leukemia cells initiating dierentiation (Kozopas et al., 1993) . As demonstrated by transfection studies, MCL1 can enhance the survival of hematopoietic cells and other cell types placed under apoptosis-inducing conditions. However, the enhancement produced by MCL1 may be more short-term than that produced by BCL2 (Reynolds et al., 1994; Zhou et al., 1997) .
Since its identi®cation by dierential cloning, MCL1 has been found to exhibit a highly regulated pattern of expression, increasing in expression under a variety of conditions and in various cell types. We have characterized its expression in the ML-1 human myeloblastic leukemia cell line, which can be induced to dierentiate along the monocyte/macrophage pathway with the phorbol ester TPA (Craig et al., 1984) . We have termed MCL1 an`early-induction' gene in this system, due to its rapid increase (within 1 ± 3 h) through increased transcription (Kozopas et al., 1993; Yang et al., 1996) . The increase in mRNA, which is maximal at *3 h, is accompanied by an increase in the MCL1 protein, maximal at 3 ± 6 h . This increase in expression occurs before the appearance of markers of monocyte/macrophage differentiation or the accumulation of dierentiating cells in G0/ G1 phase of the cell cycle (Craig et al., 1984) . In human tissues in vivo, MCL1 also demonstrates tissueand dierentiation-stage speci®city (Krajewski et al., 1995) . Based on its pattern of expression and the eects seen upon gene transfer, increased expression of MCL1 has been suggested to provide rapid, short-term protection of cell viability (Reynolds et al., 1994; Zhou et al., 1997) . However, the mechanisms that underline the rapid inducibility of MCL1 have not been elucidated.
In ML-1 cells, MCL1 undergoes a rapid increase in expression upon exposure to certain chemotherapeutic, as well as dierentiation-inducing, agents. This was ®rst observed with the microtubule-disrupting agents colchicine and vinblastine , and has been since seen with certain DNA damaging agents such as ionizing radiation (Zhan et al., 1997) . While cells exposed to TPA undergo dierentiation and remain viable, cells exposed to these chemotherapeutic agents eventually undergo cell death by apoptosis. This cell death occurs over 2 ± 3 days and thus considerably after the increase in MCL1 at 3 h. No increase in MCL1 occurs in cells exposed to a wide variety of other agents including 1b-D-arabinofuranosyl cytosine (araC), daunorubicin, paclitaxel, or cytochalasin B, indicating that the increase is not a nonspeci®c response to all chemotherapeutic or cytoskeletaldirected agents .
In addition to the BCL2 family, members of the MAP kinase family, such as the extracellular signal regulated kinases (ERK1 and -2) and c-jun N-terminal kinases (JNKs), also appear to play an important role in the regulation of cell survival (Canman and Kastan, 1996; Chen et al., 1996; Xia et al., 1995) . For example, recent evidence suggests that the balance between ERK and JNK activation determines viability in neuronal PC12 cells, with a predominance of ERK activation promoting viability and a predominance of JNK activation promoting death (Xia et al., 1995) . Activation of ERKs occurs by phosphorylation, which is carried out through a cascade involving RAS, RAF, and MAP/ERK kinase (MEK) (Canman and Kastan, 1996) . Paralleling the ®ndings in PC12 cells, a RAS/ RAF/ERK-mediated pathway has been implicated in the maintenance of viability in hematopoietic cells dependent on IL-3 or GM-CSF (Kinoshita et al., 1995b; Sakamaki and Yonehara, 1994; Sato et al., 1993) . The mechanisms through which ERK/MAP kinases aect viability are not well understood, although their well-characterized ability to aect gene expression could be involved (Davis, 1995) .
The fact that the BCL2 and MAP kinase families have both been implicated in the control of cell viability suggests the hypothesis that RAS/RAF/ ERK-stimulated enhancement of cell survival might be mediated through eects on the expression of BCL2 or other BCL2 family members. In this regard, hematopoietic 32D cells transfected with, and induced to express, an oncogenic form of RAS were found to exhibit increased BCL2 expression and enhanced cell survival (Kinoshita et al., 1995a) . However, a careful examination of the time course indicated that BCL2 protein levels did not increase until after the RASinduced enhancement of survival had begun to become apparent, although an increase in BCL2 mRNA could be seen at an earlier time. Furthermore, 32D cells transfected with v-RAF exhibited no change in BCL2 protein levels despite exhibiting enhanced survival (Cleveland et al., 1994) . While these ®ndings further supported a role for RAS/RAF/ERK-mediated pathways in cell survival, they did not provide compelling evidence that the primary mechanism of this eect involved alterations in BCL2 protein levels.
In the studies described here, we set out to gain a better understanding of the signal transduction pathway(s) that regulate MCL1 expression, using the ML-1 cell line. We chose ML-1 for several reasons, including the fact that we have extensively characterized the agents that aect MCL1 expression using these cells Yang et al., 1995) . In addition, the pattern of expression of MCL1 in myeloid cells in vivo was found to be similar to that seen in dierentiating ML-1 cells, with MCL1 being expressed in the early stages of dierentiation and downregulated at later stages (Krajewski et al., 1995) . Thus, conclusions about MCL1 regulation derived from this cell line in vitro might later be tested and prove relevant in animal or human systems in vivo. Another attractive feature of the ML-1 cell model was that MCL1 expression increases in response to two dierent classes of stimuli, agents that induce dierentiation (but not death) and agents that induce death (but not dierentiation). This would allow us to compare these two classes to determine whether similar or distinct signal transduction pathways are involved. Finally, the increase in MCL1 occurs only in response to speci®c agents within these two classes. Thus, MCL1 increases in response to monocyte/macrophage dierentiationinducing agents such as TPA, but not granulocyte dierentiation-inducing agents such as retinoic acid . Analogously, as mentioned, MCL1 expression increases in response to microtubuledisrupting but not all chemotherapeutic agents. While expression of MCL1 is highly regulated and has been most extensively studied in myeloid cells, ML-1 and other immature human myeloid cell lines are very dicult to transfect, limiting the approaches that can be used to study gene regulation. Therefore, the variety of agents with known eects on MCL1 in this system provided a useful tool for the identi®cation of the signal transduction pathways of interest.
The experiments described in this report were carried out in three phases. First, since MCL1 expression increases in response to TPA and other active phorbol derivatives , we tested for the involvement of PKC, using an approach entailing PKC inhibition or downregulation. Second, since ERKs can be activated by PKC and are involved in the regulation of early response genes (Whitmarsh et al., 1995) , we assessed the possibility that they might participate in the increase in MCL1; this possibility was evaluated by monitoring ERKs under conditions that do versus do not increase MCL1, and by using a speci®c inhibitor of MEK. Third, since MCL1 expression also increases in response to colchicine and vinblastine, we used analogous approaches to further explore the role of the cytoskeleton. The results of these studies de®ne a signal transduction pathway in which inhibition of microtubule assembly acts through PKC to promote ERK phosphorylation. This phosphorylation event, in turn, contributes to increased MCL1 expression and enhancement of cell viability. Overall, the MCL1 viability-enhancing gene is the target of a cytoskeletal disruption-induced ERK-mediated signaling pathway.
Results

Role of PKC activation and ERK1/2 phosphorylation in increased MCL1 expression
As a ®rst step in delineating the signal transduction pathway that leads to increased MCL1 expression in ML-1 cells, we tested for the involvement of protein kinases such as PKC Nishizuka, 1992) . The approach taken involved preincubating cells with kinase inhibitors, followed by the addition of MCL1-inducing agents (5610 710 M TPA, 20 mM colchicine, or 2 mg/ml vinblastine). Expression of the MCL1 protein was then monitored 6 h later, when the increase in MCL1 approaches a maximum (Kozopas et al., 1993; Yang et al., 1995 Yang et al., , 1996 Preincubation with 100 nM staurosporine for 1 h was found to block the increase in MCL1 expression produced by either TPA or the microtubule-disrupting agents (data not shown). In fact, the presence of staurosporine, either by itself or in combination with one of these MCL1-inducing agents, caused MCL1 expression to decline to below the low basal level seen in untreated control cells. In contrast, staurosporine did not have any consistent eect on BCL2 expression and had little eect on cell viability. This ®nding suggested that a staurosporine-sensitive protein kinase played a role in increasing MCL1 expression.
Inhibition of PKC by other means also interfered with the increase in MCL1 expression. Thus, preincubation with light-activated calphostin C for 1 h had an inhibitory eect essentially identical to that seen with staurosporine. The only dierence observed was that the eects of TPA on MCL1 expression, as compared to those of the microtubule-disrupting agents, exhibited dierential sensitivity to the inhibitor: a concentration of 500 nM calphostin C was required to completely inhibit the increase in MCL1 seen with TPA (a 250 nM concentration producing partial inhibition; data to be published elsewhere), while a concentration of 100 nM calphostin C completely inhibited the increase in MCL1 seen with the microtubule-disrupting agents. Downregulation of PKC by preincubation with TPA (17610 710 M for 24 h; Basu et al., 1992; Bradshaw et al., 1992; Rinaudo et al., 1995) completely inhibited the increase in MCL1 produced by either TPA or microtubule-disrupting agents (data not shown). In sum, PKC appeared to participate in the increase in MCL1 produced by both types of inducing agents.
In a variety of cell types including myeloid cells, exposure to TPA results in the activation of PKC and subsequently in the phosphorylation and activation of the MAP kinases ERK1 and -2 (Kharbanda et al., 1994; Kolch et al., 1993) . It therefore seemed likely that exposure to TPA, and possibly also the microtubule-disrupting agents, might result in an increase in ERK phosphorylation in ML-1 cells. To test this possibility, an antibody speci®c for the phosphorylated forms of ERK1 and -2 was used (Kuo et al., 1996; O'Flaherty et al., 1996) . Total ERK1/2 protein levels were monitored in parallel with an antibody that recognizes both the phosphorylated and non-phosphorylated forms. A marked increase in the phosphorylated forms of ERK1 and -2 was observed upon exposure of cells to TPA, colchicine, or vinblastine ( Figure 1a and data not shown). No change in total ERK1/2 protein levels was apparent (Figure 1b) . The increase in phosphorylation could be seen within 15 ± 30 min, and was maintained for nearly 2 h or more, with ERK2 being predominant as compared to ERK1 in terms of both phosphorylated and total protein levels. In eight independent experiments in which cells were treated with 5610 710 M TPA for 30 min, the average increase in the phosphorylated forms of ERK1/2 was estimated by densitometric scanning to be *12-fold (s.e.=2.5). Previous experiments have shown that the increase in MCL1 expression occurs within this time frame: mRNA levels begin to increase within 1 h after addition of the MCL1-inducing agents and approach a maximum at *3 h, while the protein approaches a maximum at 3 ± 6 h (Kozopas et al., 1993; Yang et al., 1995 Yang et al., , 1996 . Thus, a marked increase in ERK1/2 phosphorylation occurred within a time frame consistent with the possibility of its being an early event in increased expression of MCL1.
A series of concentrations of TPA were next tested for eects on ERK1/2 phosphorylation and MCL1 expression, to further explore the relationship between these two events. Concentrations of 1.7 ± 5610 710 M TPA produced pronounced, progressive increases in ERK1/2 phosphorylation (estimated to be ®ve-and tenfold, respectively) and MCL1 expression (*four-and eightfold; Figure 2 , lanes 4 ± 5). The concentration dependence of this increase in the MCL1 protein mirrored previous results with the mRNA . Tenfold lower concentrations of TPA (0.17 ± 0.5610 710 M) did not have pronounced eects, although ERK1/2 phosphorylation was increased slightly (by less than twofold; Figure 2b ). This small increase in ERK1/2 phosphorylation may be below a threshold necessary for increased MCL1 expression. Similar threshold eects have been observed previously, where they have been attributed to the fact that pronounced, sustained activation of ERKs is required for their translocation into the nucleus (Dikic et al., 1994; Marshall, 1995) . Overall, concentrations of TPA that caused a pronounced increase in ERK1/2 phosphorylation (in the range of ®ve-to 5tenfold) caused an increase in MCL1 expression. In contrast, concentrations that had only minor (5twofold) eects on ERK1/2 phosphorylation did not increase MCL1.
A similar concentration/response analysis was carried out using colchicine. As with TPA, the highest concentrations of colchicine tested produced marked increases in ERK1/2 phosphorylation (*5 ± 6-fold at 2 ± 20 mM; Figure 3a ± b, lanes 2 ± 3) and in MCL expression (*3.5-and ®vefold), while lower concentrations produced a smaller increase in ERK1/2 phosphorylation and no increase in MCL1 expression (0.002 ± 0.02 mM; Figure 3a ± b, lanes 5 ± 6). An intermediate concentration of 0.2 mM colchicine appeared to be a possible exception to the association between eects on ERK1/2 and MCL1, since little increase in ERK1/2 phosphorylation was seen at 30 min while some increase in MCL1 was seen at 6 h (*twofold; Figure 3a ± b, lane 4). However, a time course study revealed that continued exposure of cells to this concentration produced a moderate increase in Figure 1 Eect of TPA or microtubule-disrupting agents on expression of the phosphorylated forms of ERK1 and -2. ML-1 cells were either left untreated (lane 1), or exposed to 5610 710 M TPA (lanes 2 ± 5), or 20 mM colchicine (lanes 6 ± 9), for 15 ± 120 min. They were then assayed for the phosphorylated forms of ERK1 and -2 (ERK1-p and ERK2-p (a), and total ERK1 and -2 (b). The experiment shown is representative of three time course experiments ERK1/2 phosphorylation (*3.2-fold at 120 min; Figure 3c ), which may account for the subsequent modest increase in MCL1. Although the time course has not been monitored for each concentration of colchicine, it is likely that both the duration and the magnitude of eects on ERK1/2 phosphorylation have an impact on MCL1 expression, as in other systems (Dikic et al., 1994; Marshall, 1995) . In these experiments, only a small if any change in BCL2 expression was observed (Figure 3a , lower photograph). In sum, with colchicine as with TPA, concentrations that caused ERK1/2 phosphorylation to increase above a threshold value, in the range of threefold, caused an increase in the expression of MCL1 but had little eect on that of BCL2.
A variety of other agents that either increase, or do not increase, MCL1 expression were also tested for eects on ERK1/2 phosphorylation. On one hand, MCL1 expression in ML-1 cells is not increased by the chemotherapeutic agents araC or daunorubicin, by the cytoskeleton-directed agent cytochalasin B, or by the inducer of granulocyte dierentiation retinoic acid . These agents were found to cause only a small increase in ERK1/2 phosphorylation ( Figure 4 and data not shown; average increase of 1.7-fold+0.1 (s.e.)), reminiscent of that seen with concentrations of colchicine or TPA that did not aect MCL1 (Figures 2 ± 3). As discussed further below, paclitaxel caused a decrease in ERK1/2 phosphorylation. On the other hand, MCL1 expression was found to be increased by okadaic acid or high concentrations of the bacterial endotoxin lipopolysaccharide (4.9-(+1.4 s.e.) and three (+0.7)-fold respectively in three independent experiments). These agents caused an increase in ERK1/2 phosphorylation in ML-1 (4.9-and 3.6-fold respectively at 30 min) as in some other myeloid cells (Kharbanda et al., 1994; Liu et al., 1994) . Overall, various agents that increased MCL1 Figure 2 Eect of various concentrations of TPA on expression of the phosphorylated forms of ERK1 and -2 and on expression of MCL1. ML-1 cells were either left untreated or incubated with various concentrations of TPA. They were then assayed for the MCL1 protein after 6 h (a) or for the phosphorylated forms of ERK1 and -2 after 30 min (b) Figure 3 Eect of various concentrations of colchicine on expression of the phosphorylated forms of ERK1 and -2 and on expression of MCL1. ML-1 cells were either left untreated or incubated with various concentrations of colchicine. They were then assayed for the MCL1 and BCL2 proteins after 6 h (a), or for the phosphorylated forms of ERK1 and -2 after 30 min (b) or the indicated times (c). The experiment shown in a and b is representative of two experiments expression were found to produce a substantial increase in ERK phosphorylation, while agents that did not increase MCL1 had only subthreshold eects.
We note that all of the above MCL1-inducing agents, including okadaic acid and LPS, can have multiple eects within the cell. The ®nding that okadaic acid increased ERK phosphorylation and MCL1 expression is consistent with its action as a phosphatase inhibitor; in other words, okadaic acid may act by inhibiting the dephosphorylation of the same proteins that are phosphorylated by PKC. Alternately, okadaic acid may act through eects on other proteins not aected by PKC. The ®ndings with LPS are consistent with the fact that this agent can activate various members of the MAP kinase family, including ERKs and p38 MAP kinase (Dziarski et al., 1996; Kharbanda et al., 1994; Han et al., 1997; Liu et al., 1994) . However, the concentration of LPS required to increase MCL1 expression in ML-1 cells (100 mg/ml) was considerably higher than those used in other systems. Therefore, with LPS and with the other agents as well, it was not clear from the above data alone whether the observed eects on ERK phosphorylation resulted in increased MCL1 expression or, alternatively, whether these two eects merely occurred coincidentally.
We also tested MCL1-inducing agents for eects on JNK phosphorylation. We observed an increase in JNK phosphorylation with colchicine and vinblastine, but no increase with TPA, LPS, or okadaic acid (as assayed at a 30 min time point, data not shown). Since p38 MAP kinase can be activated by hyperosmolarity (Han et al., 1994) , we tested this condition for eects on MCL1 expression. We found that exposure to hyperosmolar conditions (0.05 or 0.1 M NaCl for 6 h) did not increase MCL1 expression. Overall, activation of MAP kinases other than ERKs was a not common property of MCL1-inducing agents. However, with speci®c agents, other MAP kinases may have a role in eects on MCL1 (e.g., JNK in the case of the microtubule-disrupting agents or other MAP kinases in the case of LPS).
To determine whether the increase in ERK1/2 phosphorylation observed above with various agents was necessary for the ensuing increase in MCL1 expression, we preincubated cells with a selective inhibitor of MEK, the enzyme responsible for ERK1/ 2 phosphorylation. This inhibitor, PD 98059, specifically inhibits MEK1/2 and thus ERK1/2 phosphorylation, but does not aect other MEKs or their downstream targets including JNKs and p38 MAP kinase . We found PD 98059 to block ERK1/2 phosphorylation in the presence of colchicine and vinblastine ( Figure 5a ) and to strongly blunt the increase seen in the presence of TPA ( Figure  5b , compare +PD 98059 to 7PD 98059 at 60 ± 150 min), consistent with the reports of others (Plevin et al., 1996; Wilkie et al., 1996) . Correspondingly, PD 98059 inhibited the increase in MCL1 expression produced by either type of agent ( Figure 5c , upper photograph). The eect of PD 98059 on the response to TPA was particularly instructive: TPA alone produced an increase in ERK phosphorylation of *sevenfold (+0.7; s.e.) at 60 ± 150 min ( Figure 5b , lanes 5, 7, 9 and 11). However, in the presence of PD 98059, this increase was only 2.8-fold (+0.15; s.e.; Figure 5b , lanes 6, 8, 10 and 12) and thus was below the above-described 4threefold threshold necessary for increased MCL1 expression. In parallel, MCL1 expression was increased as expected in cells exposed to TPA alone ( Figure 5c , lane 3, upper photograph) but was not increased above the untreated control level in cells exposed to both PD 98059 and TPA (Figure 5c , lane 4, upper photograph). These results were again suggestive of a threshold eect, since the subthreshold (5threefold) increase in ERK phosphorylation seen in the presence of the inhibitor plus TPA was associated with little if any increase in MCL1 above the level present in untreated controls, while a moderate further increase in ERK phosphorylation (to *sevenfold), seen with TPA alone, was associated with maximal eects on MCL1. This distinct pattern of eects on MCL1 expression diered from the pattern of BCL2 expression monitored in parallel, where BCL2 was moderately decreased in the presence of the various agents ( Figure 5c , lower photograph). Overall, when cells were preincubated with PD 98059, ERK1/2 phosphorylation was maintained below the threshold value required for MCL1 induction, and the increase in MCL1 normally produced by TPA or the microtubuledisrupting agents was inhibited.
In addition to inhibiting the increase in MCL1 produced by TPA and the microtubule-disrupting agents, PD 98059 also inhibited the increase produced by okadaic acid or LPS. In cells preincubated with PD 98059 prior to exposure to either of these inducers, MCL1 levels were maintained in the range of or below those seen in untreated control cells (Figure 5d ). Again, the distinct pattern of eects on MCL1 expression diered from eects on BCL2 expression, where a decrease was seen with some agents but was not aected in any consistent fashion by PD 98059. Overall, the agents that increase MCL1 expression have in common the property of increasing ERK activation above a threshold value of about threefold. These agents have additional eects within the cell (e.g. colchicine and vinblastine also increase JNK activation), and some of these eects may contribute to the eects on MCL1. However, the eects on ERK activation appear to be critical for eects on MCL1, since the increase in MCL1 expression is inhibited when PD 98059 is used to maintain ERK activation below the threshold value.
Association between inhibition of increased MCL1 expression and enhancement of cell death
Using an inducible transfection system, we previously showed that induction of MCL1 expression results in an enhancement of viability in FDC-P1 cells (Zhou et al., 1997) . We therefore hypothesize that the rapid increase in MCL1 expression seen in ML-1 cells treated with TPA plays a role in the maintenance of viability during the initiation of dierentiation. This hypothesis is consistent with the ®nding that the low basal level of MCL1 expression seen in immature, unstimulated ML-1 cells is below that necessary to produce viabilityenhancing eects upon transfection, while the increased level of MCL1 seen in ML-1 cells initiating differentiation is well within the range known to produce viability-enhancing eects Zhou et al., 1997) . We therefore expected that, in ML-1 cells dierentiating in response to TPA, PD 98059-induced inhibition of the increase in MCL1 expression might result in inhibition of cell viability. We did not necessarily expect the PD 98059-induced decrease in basal levels of MCL1 to have an eect on the viability of immature cells not treated with TPA, since these cells express only low levels of MCL1 which are probably not sucient to aect viability. Indeed, we found that PD 98059 was essentially non-toxic when applied to immature cells (Figure 6a , ®rst set of bars). This ®nding made it readily feasible to test the expectation that PD 98059 might enhance cell death when applied in combination with TPA, or with other agents capable of increasing MCL1 expression. To this end, we monitored the viability of cells exposed to TPA in the absence or presence of PD 98059 (Figure 6a ). When either PD 98059 or TPA was administered alone, cell death was minimal (510% for TPA minus PD 98059 at 48 h). However, when the two drugs were administered in combination, cell death was considerable (450% for TPA plus PD 98059 at 48 h; Figure  6a ). Apoptosis increased progressively with increasing duration of TPA treatment, consistent with the possibility that increasing apoptosis occurred as increasing numbers of cells initiated the differentiation program (in response to TPA) without an increase in MCL1 (due to the presence of PD 98059). In addition, two dierent concentrations of TPA were tested, both of which cause dierentiation (Craig et al., 1984) ; when either concentration was administered in combination with PD 98059, approximately equivalent amounts of apoptosis were seen at 48 h. Analogous results were Figure 5 Eect of inhibition of ERK1/2 phosphorylation on increased MCL1 expression. ML-1 cells were preincubated in the absence (7) or presence (+) of the MEK inhibitor PD 98059 (50 mM) for 90 min and then subjected either to no further treatment (untreated), or exposed to 20 mM colchicine, 2 mg/ml vinblastine, or 5610 710 M TPA (a ± c), or 50 ng/ml okadaic acid or 100 mg/ml LPS (d). Cells were then assayed for ERK1/2 phosphorylation after an additional 30 min (a) or 30 to 180 min (b), or assayed for MCL1 (upper photograph) and BCL2 (lower photograph) expression after 6 h (c ± d). Cell viability assayed at the end of the incubation was 492% for all samples. The results shown in c are representative of three independent experiments in which MCL1 was assayed in all three and BCL2 was assayed in two. MCL1 levels were found by densitometric scanning to be increased 5.2-fold (+1.0 s.e.) in the presence TPA, 6.1-fold (+1.8) in the presence of colchicine, and 7.1-fold (+2.0) in the presence of vinblastine. In the presence of PD 98059 (lane 2), MCL1 levels averaged 0.25-fold (+0.09) those present in untreated control cells; these levels in the presence of PD 98059 plus TPA, colchicine, or vinblastine averaged 0.9-fold (+0.2), onefold (+0.3), and 0.6-fold (+0.1) those present in untreated control cells. BCL2 levels in the various treated samples (lanes 2 ± 8) in d averaged 0.6-fold (+0.07 s.e.) those present in untreated control cells. In d, MCL1 levels in the presence of PD 98059 were 0.26-fold those present in untreated control cells; these levels in the presence of PD 98059 plus okadaic acid, LPS, or TPA were 0.7-, 0.1-, and 0.8-fold those present in untreated control cells. BCL2 levels in the various samples (lanes 2 ± 8) in d averaged 0.7-fold (+0.1 s.e.) those present in untreated control cells obtained using another MCL1-inducing agent, colchicine: while death with colchicine alone is known to occur slowly (*20% at 48 h in Figure 6a , Yang et al., 1996) , the combination of PD 98059 and colchicine caused rapid cell death. The rapidity of death varied somewhat from experiment to experiment, more than 80% dead cells being seen within 24 h in some experiments and within 48 h in others. Overall, PD 98059-induced inhibition of increased MCL1 expression was associated with conversion of a dierentiation response to cell death in the case of TPA and acceleration of cell death in the case of the microtubule-disrupting agent.
For purposes of comparison, PD 98059 was also used in combination with cisplatin, which causes cells to accumulate in G2 phase of the cell cycle (Demarcq et al., 1994; Sorenson and Eastman, 1988) while microtubule-disrupting agents cause accumulation in M phase. Unlike the microtubule-disrupting agents, cisplatin was not found to increase expression of MCL1 (data not shown). As in previous experiments (Demarcq et al., 1994) , application of cisplatin alone, even for a brief 2 h exposure, caused cell death ( Figure  6b ). In contrast to the results with colchicine, the combined application of PD 98059 and cisplatin did not cause an increase in cell death beyond that observed with cisplatin alone. Thus, application of PD98059 caused no further cell death in cells exposed to an agent that did not aect MCL1, in contrast to the striking enhancement of cell death, associated with inhibition of MCL1 expression, seen in cells exposed to TPA or colchicine. These ®ndings do not prove that PD 98059-induced inhibition of increased MCL1 expression is responsible for loss of cell viability. However, they complement previous studies demonstrating that induction of MCL1 enhances viability (Zhou et al., 1997) , by showing that inhibition of MCL1 induction is associated with cell death.
Triggering of the increase in MCL1 expression by microtubule disruption
The above experiments suggested that a common signal transduction pathway was involved in the increase in MCL1 expression produced by the microtubuledisrupting agents and TPA. However, while TPA can have direct eects on PKC (Blumberg, 1991; Nishizuka, 1988 ), a primary action of colchicine and vinblastine is inhibition of microtubule assembly resulting in microtubule disruption (Carney et al., 1986; Crossin and Carney, 1981) . It therefore seemed likely that the eects of these agents on microtubules might mediate their eects on MCL1. As a ®rst step in examining this possibility, we used various concentrations of colchicine to compare the concentrationresponsiveness of the two eects. Using immunofluorescence microscopy, we found that the network of microtubules seen in untreated cells (Figure 7a ) was not altered in cells exposed to concentrations of colchicine that do not increase MCL1 expression (0.002 ± 0.02 mM; Figure 3a) . However, the microtubule network was not discernible in cells exposed to concentrations of colchicine or vinblastine that do increase MCL1 expression (0.2 ± 20 mM colchicine, Figure 7c ; or 0.2 ± 2 mg/ml vinblastine, data not shown). In addition, another microtubule-disrupting agent was also found to increase MCL1 expression (nocodazole at 5 ng/ml), while an inactive colchicine derivative that does not disrupt microtubules did not increase MCL1 (gamma-lumicolchicine at 2 ± 20 mM). In contrast to colchicine and vinblastine, TPA did not cause microtubule disruption (data not shown). These observations suggested an association between eects on microtubules and the increase in MCL1 expression produced by colchicine and vinblastine, but not that produced by TPA.
To further assess the role of microtubule disruption in increased MCL1 expression, we blocked this disruption using paclitaxel, applied at concentrations that stabilize microtubules (Manie et al., 1993; Shinohara-Gotoh et al., 1991) . We found that paclitaxel inhibited the microtubule-disrupting eects of colchicine and vinblastine (Figure 8a ± b) . Accordingly, it inhibited the increase in MCL1 expression produced by these two agents, although it did not inhibit the increase produced by TPA (Figure 8c ). In agreement with the decrease in ERK1/2 phosphorylation noted above (Figure 4) , paclitaxel also decreased basal MCL1 levels ( Figure 8c , lane 2) as reported previously . Paclitaxel was non-toxic within the short time frame used for assay of MCL1 expression (Figure 8 ), although prolonged exposure (*2 days or more) had the expected result of cell death (Bhalla et al., 1993; Ibrado et al., 1996) . In sum, microtubule disruption appeared to play a role in the Figure 6 Eect of inhibition of ERK1/2 phosphorylation on the viability of cells exposed to TPA or colchicine. ML-1 cells were incubated in the absence (7) or presence (+) of PD 98059 (50 mM) for 90 min, followed by addition of the indicated concentrations of TPA or colchicine for an additional 12 to 48 h (a). Alternatively, cells were incubated for 2 h with the indicated concentrations of cisplatin, washed, and exposed to PD 98059 for 12 to 48 h (b). For the ®nal 30 min of incubation, Hoechst 33342 was added to all samples for assay of apoptosis. In a, the points shown represent the mean+s.e. of two to three experiments. Analysis of variance with Schee testing, using logcoded values to achieve a normal distribution, revealed that the presence versus the absence of PD 98059 produced a signi®cant (P50.01) eect on the percent apoptotic cells for both concentrations of colchicine and for the 5610 710 M concentration of TPA. For the 1.7610 710 M concentration of TPA, a signi®cant dierence between the presence versus the absence of PD 98059 was seen at the 48 h time point, as determined using a one tailed t-test (P50.05). There was no dierence between the two concentrations of colchicine, as found previously ; this was true both when colchicine applied alone (2 mM versus 20 mM colchicine, 7PD 98059), and when it was applied in the presence of PD 98059 (2 mM versus 20 mM colchicine, +PD 98059). Likewise, there was no dierence between the two concentrations of TPA, when applied alone (1.7 versus 5610 710 M TPA, 7PD 98059), or when applied in the presence of PD 98059 (1.7 versus 5610 710 M TPA + PD 98059) increase in MCL1 expression produced by colchicine and vinblastine, but not that produced by TPA. We also followed the time course of the eect of colchicine on microtubule disruption, for comparison to eects on ERK1/2 phosphorylation. Loss of the microtubule lattice was found to be complete within 2 h in cells treated with 2 mM colchicine. Thus, increased ERK1/2 phosphorylation (Figure 1 ) occurred prior to complete loss of the microtubule network. All these events preceded colchicine-induced cell cycle changes, which became evident within *6 h and were more fully manifested at 24 h (*16% and *36% of cells were in G2/M phase at 6 h and 24 h, respectively, after exposure to 2 mM colchicine, as compared to a value of *8% for untreated control cells). These ®ndings reinforced the above observation that the increase in ERK1/2 phosphorylation that triggers MCL1 expression is an early event, as it occurs prior to the completion of microtubule disassembly and colchicine-induced changes in cell cycle distribution.
In review, the signal transduction pathway leading to increased expression of MCL1 appeared to involve inhibition of microtubule assembly, activation of PKC, and increased phosphorylation of ERK1/2, operating in this sequence. This sequence is based upon the following reasoning. The target of TPA is likely PKC, in accord with previous ®ndings in this system (Guan et al., 1989; Sakagami et al., 1984) , since inhibition or downregulation of PKC inhibited the TPA-induced increase in MCL1. PKC appeared to lie upstream of ERK phosphorylation, since inhibition of ERK phosphorylation inhibited the TPA-induced increase in MCL1 (Figure 5 ). This portion of the pathway involving PKC and ERKs appeared similar for the microtubule-disrupting agents and TPA, as the eects of both types of agents were sensitive to inhibitors of PKC and ERK phosphorylation. However, microtubule disruption appeared to lie upstream of PKC, since the increase in MCL1 produced by microtubuledisrupting agents was inhibited by paclitaxel but the increase produced by TPA was not (Figure 8 ).
Discussion
The ®ndings described here outline the signal transduction pathway mediating the increase in MCL1 expression seen in ML-1 cells exposed to speci®c dierentiation-or apoptosis-inducing stimuli. An increase in ERK phosphorylation is a central component of this pathway. This increase can be triggered through inhibition of microtubule assembly, the target of colchicine and vinblastine, and activation of PKC, the target of TPA. The pathway is rapidly inducible, as ERK phosphorylation increases within 15 ± 30 min and MCL1 expression increases with 1 h. Both events occur before the completion of microtubule disassembly at *2 h. This cytoskeletal disruption-induced, ERK-mediated pathway dramatically increases the expression of MCL1 but not BCL2.
The fact that the cytoskeleton can aect nuclear events has recently become apparent (Glanz, 1997) . In the system studied here, microtubule disassembly is associated with an increase in ERK phosphorylation and MCL1 expression. Conversely, inhibition of disassembly, upon treatment with paclitaxel, is associated with a decrease in the basal levels of ERK phosphorylation and MCL1 expression. This latter ®nding suggests that the normal process of microtubule disassembly has a role in the maintenance of basal ERK phosphorylation and MCL1 expression. In the presence of microtubule-disrupting agents, disassembly predominates over assembly, and ERK phosphorylation and MCL1 expression are increased. In order to be eective, however, the increase in ERK phosphorylation must exceed a threshold value of about threefold. Smaller increases (e.g. twofold) have no eect on MCL1 while greater increases (e.g. ®ve-to 5tenfold) have pronounced eects on MCL1. Thresh- Figure 7 Eect of colchicine on the microtubule lattice. ML-1 cells were either left untreated (a), or exposed to 0.02 mM colchicine for 6 h (b) or 2 mM colchicine for 4 h (c). The cells were then stained with an antibody directed against alpha-tubulin and viewed by immuno¯uorescence microscopy old eects have been observed previously for MAP kinases, where relatively small increases in signal strength can cause large changes in gene activation (Hill and Treisman, 1995) . The existence of a threshold level of ERK activation below which MCL1 does not increase may serve to prevent unwarranted increases in MCL1 in response to minor¯uctuations in microtubule turnover.
The increase in expression of MCL1 produced by TPA and microtubule-disrupting agents, may serve as a rapidly-inducible, transient, means of enhancing viability in cells exposed to these potentially apoptotic stimuli . The ®nding that MCL1 was regulated through an ERK-mediated pathway, and that the PD 98059 inhibitor of this pathway was noncytotoxic to immature unstimulated ML-1 cells, allowed us an additional means, besides transfection (Zhou et al., 1997) of demonstrating an association between MCL1 expression and viability-enhancement. When PD 98059 was applied concurrently with TPA or microtubule-disrupting agents, rapid, synergistic cell death occurred in association with the inhibition of MCL1 expression. In contrast, when PD 98059 was applied with cis-platin, an apoptosis-inducing agent that does not increase MCL1 expression, no further cell death occurred beyond that produced by cis-platin alone. Thus, PD 98059 did not simply enhance cell death in a non-speci®c manner, but rather did so only Figure 8 Eect of paclitaxel on microtubule disruption and increased MCL1 expression. Cells were treated with 20 mM paclitaxel for 1 h (a), or paclitaxel followed by 20 mM colchicine for an additional 6 h (b), and visualized as in Figure 7 . Alternatively, cells were incubated in the absence (7) or presence (+) of 20 mM paclitaxel for 1 h, exposed to 5610 710 M TPA, 20 mM colchicine, or 2 mg/ml vinblastine for an additional 6 h, and assayed for expression of MCL1 (upper photograph) or BCL2 (lower photograph) (c). Cell viability assayed at the end of the incubation was 492% for all samples. The experiment shown in c is representative of two independent experiments. MCL1 levels were found by densitometric scanning to be increased 8.6-fold (+0.9 s.e.) in the presence TPA alone and 5.7-fold (+1.2) in the presence of paclitaxel plus TPA. MCL1 levels were increased 11 ± 13-fold in the presence of vinblastine or colchicine alone (s.e. of 0.8 and 3.6, respectively); however, in the presence of paclitaxel plus vinblastine or colchicine (lanes 6 and 8), MCL1 levels were increased 5twofold. BCL2 levels in the various treated samples (lanes 2 ± 8) averaged 1.8-fold (+0.17 s.e.) those present in untreated control cells in combination with agents that normally cause an increase in MCL1. Although these results do not in themselves prove that MCL1 enhances survival, they are altogether consistent with the previous demonstration that MCL1 has such an eect (Zhou et al., 1997) . In other words, just as induction of an exogenously introduced MCL1 gene enhances cell survival, induction of the endogenous gene through the ERKmediated pathway described here may perform a similar function, with inhibition of this induction resulting in enhanced cell death.
Our current eorts are directed at more fully elucidating the events that lie upstream and downstream of ERK phosphorylation. Microtubule disruption has been reported to aect the expression of other genes (Botteri et al., 1990; Manie et al., 1993) and is the most upstream event so far identi®ed with respect to MCL1. However, we can at present only speculate as to how inhibition of microtubule assembly might result in increased ERK phosphorylation and increased MCL1 expression. It is known that MAP kinases associate with microtubules, and that the microtubule-associated pool can be readily activated (Ding et al., 1996; Verlhac et al., 1993) . Our data also point to the involvement of PKC, and speci®c isoforms of PKC have been recently reported to associate with microtubules (Kiley and Parker, 1995) . Phospholipase C, which produces endogenous activators of PKC has similarly been suggested to bind to tubulin and become activated by speci®c microtubule-associated proteins (Hwang et al., 1996; Itoh et al., 1996; Seedorf et al., 1994) . Thus, a plausible hypothesis might be that inhibition of microtubule assembly results in activation of phospholipase C, followed by diacylglycerol production and activation of PKC and ERK1/2.
In addition to the eects on MCL1 seen in these studies, other potential links between the cytoskeleton, RAS/RAF/MAP kinase pathways, and BCL2 family members are being uncovered. For example, BCL2 and the BCL2 family member BAD can be regulated by post-translational phosphorylation (Haldar et al., 1996 (Haldar et al., , 1997 Ito et al., 1996; May et al., 1994; Wang et al., 1996; Zha et al., 1996) . The enzymatic pathways that carry out this posttranslational modi®cation are just beginning to be characterized, although RAF has been suggested to be involved (Blagosklonny et al., 1997; Haldar et al., 1996 Haldar et al., , 1997 Wang et al., 1996) . The pathways that aect BCL2 may at least partially dier from those described here for MCL1. For example, one agent that aects the posttranslational modi®cation of BCL2 (paclitaxel) decreases expression of MCL1 while another (okadaic acid) increases expression of MCL1 (Blagosklonny et al., 1997; Haldar et al., 1996 Haldar et al., , 1997 .
In summary, the present ®nding of an ERKmediated pathway that regulates expression of MCL1, taken together with the recent demonstration of posttranslational regulation of BCL2 and BAD, indicates that a web of phosphorylation pathways act at multiple levels to regulate BCL2 family members and cell death. Overall, a variety of gene families participate in the control of cell death, with members of the BCL2 family regulating a cascade of caspase eectors (Golstein, 1997; Martin and Green, 1995) , and protein kinases including MAP kinases in turn regulating the BCL2 family.
Materials and methods
Cell culture and exposure to drugs and inhibitors ML-1 cells were grown in RPMI 1640 media (Paragon Biotech, Baltimore, MD or Bio Whittaker, Walkersville, MD) containing 7.5% fetal bovine serum (GIBCO, Grand Island, NY), and were maintained at 378C under a humidi®ed atmosphere of 5% CO 2 as described previously (Craig et al., 1984; Yang et al., 1996) . For experiments and for routine maintenance, cells were diluted to a density of 3610 5 cells/ml. TPA, colchicine, vinblastine, paclitaxel, lipopolysaccharide (from Escherichia coli 026:B6; Sigma catalogue #L2654, Sigma catalogue #L6529 from Escherichia coli 055:B5 being ineective in inducing MCL1 expression), okadaic acid, araC, daunorubicin, retinoic acid, and cytochalasin B were obtained from Sigma Chemical Company (St Louis, MO). Platinol (cisplatin) was obtained from Bristol-Myers Squibb Co. (Princeton, NJ). Staurosporine, calphostin C, and PD 98059 were purchased from Calbiochem (San Diego, CA).
The MCL1-inducing agents TPA, colchicine, and vinblastine were used at concentrations shown previously to cause a maximal increase in MCL1 expression in ML-1 cells at 3 ± 6 h. For TPA, this concentration was 5610 710 M which causes translocation of PKC from the cytosol to the membrane within minutes (Guan et al., 1989) and dierentiation to monocyte/macrophages over the next 3 days (Craig et al., 1984) . For the microtubule-disrupting agents, these concentrations were 20 mM colchicine and 0.2 ± 2 mg/ml vinblastine, which cause *50% cell death by apoptosis with 3 days of exposure . The rationale for using these agents at concentrations that cause a maximal increase in MCL1 was that the eect of various inhibitors on this increase was to be tested and it was important to ascertain whether the inhibitors could block the eects of maximally eective concentrations of the MCL1-inducing agents. Agents known not to increase MCL1 expression (retinoic acid, araC, daunorubicin, cytochalasin B), used for comparative purposes, were applied at concentrations that have been previously characterized . Cisplatin was applied using concentrations and an exposure time that cause accumulation in G2 phase of the cell cycle, followed by apoptotic cell death (Demarcq et al., 1994) . Paclitaxel was used at a concentration (20 mM) in the range previously reported to stabilize microtubules (Manie et al., 1993; Shinohara-Gotoh et al., 1991) and inhibit the eects of microtubule-disrupting agents (Manfredi et al., 1982 ).
Inhibitors to be tested for eects on MCL1 expression were applied using the following conditions. Staurosporine and calphostin C, used at concentrations that inhibit PKC activity (Hohmann et al., 1992; Rinaudo et al., 1995) were preincubated with cells for 1 h before addition of the MCL1-inducing agents. Calphostin C was light activated by weighing out and preparing the stock under standard conditions of laboratory lighting, with all further experimental manipulations being carried out in the dark. The same drug stock was used for all experiments. These procedures were adopted because preliminary tests showed that without light activation the drug had no eect, while extensive light activation (during the entire 1 h preincubation of cells with calphostin C) caused essentially complete cytotoxicity. PD 98059 was applied at a concentration in standard use for inhibition of MEK1,2 (50 mM; Alessi et al., 1995; , and was preincubated with cells for 1.5 h before addition of the MCL1-inducing agents.
Assay of cell viability
Cell death by apoptosis was assayed by staining cells with uorescent dyes. The method utilizing ethidium bromide and acridine orange has been previously described in detail (Duke, 1991; Zhou et al., 1997) . Brie¯y, ethidium bromide stains only cells that have lost membrane integrity (orange staining). Acridine orange stains all cells (green staining), which can then be scored as being either non-apoptotic (nuclear appearance unchanged as compared to normal non-drug treated cells) or apoptotic (densely staining condensed and/or fragmented nucleus). This protocol allows one to detect cells that are undergoing apoptosis while still maintaining membrane integrity. Cell viability was scored as the percentage of cells that retained a normal nuclear morphology and membrane integrity. Alternately, viability was assayed by incubating cells in tissue culture medium with Hoechst 33342 dye (2 mg/ml) for 30 min at 378C. As in the above assay, apoptotic cells exhibit highly condensed or fragmented nuclei, and occasionally exhibit unfragmented nuclei with condensation at the margins. In addition, nuclear staining is intense in apoptotic cells but faint and diuse in non-apoptotic cells. In both of the above assays, cells were examined using a UV uorescence microscope (Nikon), and at least 200 cells were scored for each sample.
Western blotting
Expression of the MCL1 protein was monitored using the polyclonal anti-MCL1 antibody used previously Zhou et al., 1997) . Western blotting techniques were as described previously with minor modi®cations . Whole cell lysates from 1610 6 cells were prepared using either the previously described protocol or the manufacturer's protocol for detection of ERK1 and -2 proteins. For detection of MCL1, cell lysates were boiled for 5 min and subjected to electrophoresis on a sodium dodecyl sulfate (SDS)/polyacrylamide gel (10%), followed by electrotransfer to polyvinylidene¯uoride membranes (Millipore, Bedford, MA). The membranes were incubated overnight in a blocking solution consisting of 5% nonfat dry milk in phosphate-buered saline (PBS). They were then washed three times (5 min each) in PBS, and incubated for 1 h with the anti-MCL1 primary antibody (IgG fraction, puri®ed as described previously Zhou et al., 1997) ), in a solution of PBS containing 3% bovine serum albumin (BSA) and 0.05% sodium azide. After again washing with PBS, the membranes were incubated for 1 h with horseradish peroxidase conjugated goat anti-rabbit IgG as the secondary antibody (Pierce, Rockford, IL; in PBS). After a ®nal wash, the MCL1 protein was detected by chemiluminescence (Amersham, Arlington Heights, IL).
The MAP kinases ERK1 and -2 and SAPK/JNK, and their phosphorylated forms, were detected using antibodies directed against total ERK1/2 or SAPK/JNK (phosphorylation state-independent) or antibodies speci®c for the phosphorylated ERK1/2 or SAPK/JNK forms. The latter are sensitive to the phosphorylation that occurs as part of activation of ERK1/2 and SAPK/JNK (on tyrosine 204 of ERK1, tyrosine 185 of ERK2, and threonine 183 and tyrosine 185 of SAPK/JNK). Sample preparation, gel electrophoresis, and Western blot analysis were performed according to the protocol provided by the supplier of the antibodies (New England Biolabs, Beverly, MA): ML-1 cells (2610 6 ) were pelleted, washed once with cold PBS, and lysed by addition of 100 ml of SDS sample buer containing 62.5 mM Tris-HCl (pH 6.8), 2% w/v SDS, 10% glycerol, 50 mM dithiothreitol, 0.1% w/v bromophenol blue. The samples were sonicated for 12 s boiled for 5 min, cooled, and microcentrifuged for 5 min. The supernatants obtained (20 ml representing 4610 5 cells) were subjected to electrophoresis and electrotransferred. Membranes were washed with Tris-buered saline (TBS) (2 M Tris-HCl (pH 7.6), 0.137 M NaCl) for 5 min and then incubated with blocking buer (0.1% Tween-20, 5% BSA in 16TBS) for 1 ± 3 h. After removal of the blocking buer, the membranes were incubated overnight (48C) with the primary antibody diluted 1:1000. The membranes were then washed three times (5 min each) in TBS containing 0.1% Tween-20 (TBST), incubated for 1 h with horseradish peroxidase-conjugated goat antirabbit IgG secondary antibody (Pierce, Rockford, IL) in blocking buer. The membranes were washed a ®nal time and the bands were detected by chemiluminescence. Standards consisting of phosphorylated versus non-phosphorylated MAP kinases (provided by the supplier of the antibodies) con®rmed that both of these were detected by the antibody that was not sensitive to phosphorylation state, while only the phosphorylated form was detected by the phosphorylation sensitive antibody.
Some Western blots were subjected to densitometric scanning. Autoradiographs in which the bands were not overexposed (not necessarily only those shown in the ®gures) were scanned using a Molecular Dynamics Personal Densitometer (Molecular Dynamics, Sunnyvale, CA), the more abundant ERK2 being scanned together with ERK1 because of the physical proximity of the bands on the autoradiographs. Images were quantitated using the ImageQuant program (Molecular Dynamics). In performing these scans, the emphasis was primarily on con®rming results that could be observed by visual inspection (e.g., con®rming the presence of a substantial versus a minor increase in band intensity) rather than on obtaining an extremely precise estimate of the magnitude of the increase.
Immuno¯uorescence microscopy
Cytospin slides were prepared using 3610 5 cells (in volume of 50 ml) for each slide. The cells were ®xed in methanol for 2 min, followed by permeablization in 0.5% Triton X-100 (in PBS) for 2 min. The cells were then washed twice for 1 min with PBS and incubated for 30 min with a monoclonal antibody to alpha-tubulin (Sigma Immunochemical Company, St Louis, MO; diluted 1:500) in a humidi®ed atmosphere. After washing three times (2 min each) with PBS, the cells were incubated with FITCconjugated goat-anti-mouse IgG (Southern Biotechnology Associates Inc., Birmingham, AL; diluted 1:20) for 1 h in a humidi®ed atmosphere. After a ®nal wash, the cells were mounted in 1% N-propyl-gallate (in a mixture of 50% PBS and 50% glycerol).
Cell cycle analyses
DNA content distribution was assayed using minor modi®cations of previously described methods (Sorenson and Eastman, 1984) . Brie¯y, 1610 6 cells were collected by centrifugation, washed with PBS, and ®xed in a PBS/95% ethanol solution (mixed in a 1:3 v/v ratio), and stored overnight at 48C. The next day, the cells were washed in PBS, resuspended in 250 ml of propidium iodide solution (100 mg/ml propidium iodide, 1 mg/ml RNase A, in PBS), and incubated for 30 min at 378C. Cell cycle analysis was performed using a FACscan Plus¯ow cytometer (Becton Dickinson, San Jose, CA).
